Induced Pluripotent Stem Cells as a Disease Modeling and Drug Screening Platform

被引:136
|
作者
Ebert, Antje D. [1 ,2 ,3 ]
Liang, Ping [1 ,2 ,3 ]
Wu, Joseph C. [1 ,2 ,3 ,4 ]
机构
[1] Stanford Univ, Dept Med, Div Cardiol, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Radiol, MIPS, Stanford, CA 94305 USA
[3] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA
[4] Stanford Univ, Stanford Cardiovasc Inst, Stanford, CA 94305 USA
关键词
induced pluripotent stem cells; disease modeling; cardiovascular disease; drug screening; high-throughput screening; LONG QT SYNDROME; TORSADE-DE-POINTES; HERG POTASSIUM CHANNEL; HUMAN SOMATIC-CELLS; INTERVAL PROLONGATION; IPS CELLS; EFFICIENT GENERATION; CARDIAC-ARRHYTHMIA; CARDIOMYOCYTES; FIBROBLASTS;
D O I
10.1097/FJC.0b013e318247f642
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Induced pluripotent stem cells (iPSCs) hold great hopes for therapeutic application in various diseases. Although ongoing research is dedicated to achieving clinical translation of iPSCs, further understanding of the mechanisms that underlie complex pathogenic conditions is required. Compared with other classical models for studying diseases, iPSCs provide considerable advantages. A newly emerging application of iPSCs is in vitro disease modeling, which can significantly improve the never-ending search for new pharmacological cures. Here, we will discuss current efforts to create iPSC-dependent patient-specific disease models. Furthermore, we will review the use of iPSCs for development and testing of new therapeutic agents and the implications for high-throughput drug screening.
引用
收藏
页码:408 / 416
页数:9
相关论文
共 50 条
  • [21] Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening
    Sharma, Arun
    Wu, Joseph C.
    Wu, Sean M.
    STEM CELL RESEARCH & THERAPY, 2013, 4
  • [22] Generation of Hepatobiliary Cell Lineages from Human Induced Pluripotent Stem Cells: Applications in Disease Modeling and Drug Screening
    Pasqua, Mattia
    Di Gesu, Roberto
    Chinnici, Cinzia Maria
    Conaldi, Pier Giulio
    Francipane, Maria Giovanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (15)
  • [23] Myogenic differentiation of VCP disease induced pluripotent stem cells: A novel platform for drug discovery
    Llewellyn, Katrina J.
    Nalbandian, Angele
    Weiss, Lan N.
    Chang, Isabela
    Yu, Howard
    Khatib, Bibo
    Tan, Baichang
    Scarfone, Vanessa
    Kimonis, Virginia E.
    PLOS ONE, 2017, 12 (06):
  • [24] Pluripotent stem cells for disease modeling and drug screening: new perspectives for treatment of cystic fibrosis?
    Ulrich Martin
    Molecular and Cellular Pediatrics, 2 (1)
  • [25] A new era of disease modeling and drug discovery using induced pluripotent stem cells
    Wonhee Suh
    Archives of Pharmacal Research, 2017, 40 : 1 - 12
  • [27] Unlocking the potential of induced pluripotent stem cells for neonatal disease modeling and drug development
    Liu, Ziyi
    Lami, Bonny
    Ikonomou, Laertis
    Gu, Mingxia
    SEMINARS IN PERINATOLOGY, 2023, 47 (03)
  • [28] Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery
    Singh, Vimal K.
    Kalsan, Manisha
    Kumar, Neeraj
    Saini, Abhishek
    Chandra, Ramesh
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2015, 3
  • [29] Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective
    Bekhite, Mohamed M.
    Schulze, P. Christian
    CELLS, 2021, 10 (12)
  • [30] Applications of Patient-Specific Induced Pluripotent Stem Cells; Focused on Disease Modeling, Drug Screening and Therapeutic Potentials for Liver Disease
    Chun, Yong Soon
    Chaudhari, Pooja
    Jang, Yoon-Young
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2010, 6 (07): : 796 - 805